# Hubert Serve

Source: https://onco.cc/people/hubert-serve/  
OnCo record `hubert-serve` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leukaemia specialist heading haematology and oncology at University Hospital Frankfurt and co-author of the pivotal RATIFY midostaurin trial.

## Summary

Hubert Serve is Director of the Department of Internal Medicine 2 (Hematology/Oncology) at University Hospital Frankfurt and a member of the UCT Frankfurt directorate. His research on FLT3 signalling in acute myeloid leukaemia contributed to the development of FLT3 inhibitors, including the international RATIFY trial of midostaurin published in the New England Journal of Medicine in 2017.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: leadership; clinician-scientist; leukaemia; haematology
- Role: Director, Department of Internal Medicine 2 (Hematology/Oncology)
- Specialisms: Acute myeloid leukaemia; Haematology; Targeted therapy

## Sources

- Institution profile: https://www.uct-frankfurt.de/ueber-uns/direktorium/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Serve+H%5BAuthor%5D

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- institutions: [University Cancer Center Frankfurt (UCT)](https://onco.cc/institutions/uct-frankfurt/)

---
JSON: https://onco.cc/api/v1/entities/hubert-serve.json